Oxford BioMedica plc (LON:OXB) had its price objective raised by N+1 Singer from GBX 7.80 ($0.10) to GBX 8.70 ($0.11) in a research note issued to investors on Thursday morning. They currently have a hold rating on the biopharmaceutical company’s stock.

OXB has been the topic of several other reports. Shore Capital reiterated a not rated rating on shares of Oxford BioMedica plc in a research report on Thursday, July 13th. Jefferies Group LLC reiterated a buy rating and issued a GBX 13 ($0.17) price target on shares of Oxford BioMedica plc in a research report on Thursday, July 13th.

ILLEGAL ACTIVITY NOTICE: This piece of content was first posted by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of international trademark & copyright legislation. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/oxford-biomedica-plc-oxb-price-target-increased-to-gbx-8-70-by-analysts-at-n1-singer/1463168.html.

In other Oxford BioMedica plc news, insider Lorenzo Tallarigo purchased 53,260 shares of the stock in a transaction dated Wednesday, May 24th. The shares were acquired at an average cost of GBX 5 ($0.07) per share, for a total transaction of £2,663 ($3,469.25). Also, insider Peter Nolan bought 249,687 shares of the firm’s stock in a transaction that occurred on Monday, July 17th. The shares were purchased at an average price of GBX 8 ($0.10) per share, for a total transaction of £19,974.96 ($26,022.62). Insiders bought 1,011,980 shares of company stock worth $8,448,961 over the last quarter.

Oxford BioMedica plc Company Profile

Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company’s segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners.

Receive News & Ratings for Oxford BioMedica plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica plc and related companies with Analyst Ratings Network's FREE daily email newsletter.